A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Latest Information Update: 20 Jun 2022
At a glance
- Drugs ASP 8062 (Primary) ; Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 15 Jun 2022 Status changed from suspended to withdrawn due to corporate strategic considerations.
- 02 Apr 2022 Status changed from recruiting to suspended.
- 05 Nov 2021 Status changed from not yet recruiting to recruiting.